ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

11 links0 made here, not in the record17 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Sep 28Oct 5Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT05525858KPMNG Study of MOlecularProfiling Guided TherapyBased on GenomicAlterations in AdvancedSolid Tumors IISeoul National University Bundactive not recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Sep 30 · ClinicalTrials.gov record · Version of 2026-09-30Version of 2026-09-30CONDITIONSNeoplasm MetastasisThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSAlectinibIntervention entry›Nov 10 · Claude Opus 5.5 · ExposureNov 18 · Rule based · ExposureExposureAtezolizumabIntervention entry›Nov 3 · Claude Opus 5.5 · ExposureNov 18 · Rule based · ExposureExposureErlotinibIntervention entry›Nov 18 · Rule based · ExposureExposureTrastuzumabEntry “Trastuzumab + Pertuzumab”, rea…›Nov 2 · Claude Opus 5.5 · ExposureNov 18 · Rule based · ExposureExposurePertuzumabEntry “Trastuzumab + Pertuzumab”, rea…›Nov 3 · Claude Opus 5.5 · ExposureNov 18 · Rule based · ExposureExposureAdo-Trastuzumab EmtansineEntry “Trastuzumab emtansine”, read b…›Nov 10 · Claude Opus 5.5 · ExposureNov 18 · Rule based · ExposureExposureVemurafenibIntervention entry›Nov 18 · Rule based · ExposureExposureBevacizumabEntry “Bevacizumab + Erlotinib”, read…›Nov 18 · Rule based · ExposureExposureEntrectinibIntervention entry›Nov 10 · Claude Opus 5.5 · ExposureNov 18 · Rule based · ExposureExposurePralsetinibIntervention entry›Nov 18 · Rule based · ExposureExposure

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Alectinib

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Alectinib”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Exposure
Exposure · 2

All judgments on this study

WhenLinkJudgeDecisionState
Sep 30The record itselfClinicalTrials.gov recordVersion of 2026-09-30Record change
Nov 2TrastuzumabClaude Opus 5.5ExposureCurrent
Nov 3AtezolizumabClaude Opus 5.5ExposureCurrent
Nov 3PertuzumabClaude Opus 5.5ExposureCurrent
Nov 10Ado-Trastuzumab EmtansineClaude Opus 5.5ExposureCurrent
Nov 10AlectinibClaude Opus 5.5ExposureCurrent
Nov 10EntrectinibClaude Opus 5.5ExposureCurrent
Nov 18AlectinibRule based · role ruleExposureAgrees
Nov 18AtezolizumabRule based · role ruleExposureAgrees
Nov 18ErlotinibRule based · role ruleExposureCurrent
Nov 18TrastuzumabRule based · role ruleExposureAgrees
Nov 18PertuzumabRule based · role ruleExposureAgrees
Nov 18Ado-Trastuzumab EmtansineRule based · role ruleExposureAgrees
Nov 18VemurafenibRule based · role ruleExposureCurrent
Nov 18BevacizumabRule based · role ruleExposureCurrent
Nov 18EntrectinibRule based · role ruleExposureAgrees
Nov 18PralsetinibRule based · role ruleExposureCurrent
As of nowNeoplasm MetastasisRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.